ZOSTAVAX™

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC, Stanford University

Conditions

Herpes ZosterShingles

Phase 3

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

CompletedNCT02519855

Merck Sharp & Dohme LLCHerpes Zoster

Start: 2015-09-11End: 2016-01-26Updated: 2018-10-30

Phase 4

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

CompletedNCT01911065

Stanford UniversityHerpes Zoster

Start: 2010-09-30End: 2011-12-31Updated: 2023-12-18

Unknown Phase

ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

CompletedNCT01600079

Merck Sharp & Dohme LLCHerpes Zoster, Shingles

Start: 2012-05-15End: 2020-10-16Updated: 2022-07-14

Related Papers

Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records

BMJ2023-11-0836 citations

Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.

2017-08-1920 citations